Abstract
Coronary atherosclerosis in younger patients is quite common (1,2), and early evidence of this disease appears to be present in many, if not most, Americans by the age of 30 (3). Autopsy studies on casualties of both war and other trauma reveal early signs of atherosclerosis in up to 70% of individuals 30 yr old or younger, with significant flow-limiting stenoses in 10% (4). Recent intravascular ultrasound studies (IVUS) from cardiac transplant recipients also confirm these reports. In these studies, where the average donor age was 33.4 ± 13.2 yr, a remarkable 51.9% of the donor coronary arteries demonstrated IVUS evidence of atheroma when these arteries were examined soon after transplantation. Furthermore, in patients under the age of 20, an astonishing 17% had evidence of disease (5).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Yater W, Traum AH, Brown WB, Fitzgerald RP, Geisler MA, Wilcox BB. Coronary artery disease in men eighteen to thirty-nine years of age: report of eight hundred sixty-six cases, four hundred fifty with necropsy examinations. Am Heart J 1948; 36: 334–337.
National Health and Nutrition Examination Survey 1976–1980 (NHANES II). 1980.
Enos W, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea. JAMA 1953; 152: 1090.
Lamm G. The epidemiology of acute myocardial infarction in young age groups. In: Roskamm H. ed. Myocardial Infarction at Young Age. Springer-Verlag, Heidelberg, 1981, pp. 5–10.
Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001; 103: 2705–2710.
Uhl GS, Farrel PW. Risk factors and natural history. In: Roskamm H. ed. Myocardial Infarction at Young Age. Springer-Verlag, Heidelberg, 1981, pp. 29–44.
Chen L, Chester M, Kaski JC. Clinical factors and angiographic features associated with premature coronary artery disease. Chest 1995; 108: 364–369.
Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E. ed. Heart Disease. W.B. Saunders, Philadelphia, 1997, pp. 1184–1288.
Hamsten A. Myocardial infarction at a young age: mechanisms and management. Vasc Med Rev 1991; 2: 45–60.
Hamsten A, de Faire U. Risk factors for coronary artery disease in families of young men with myocardial infarction. Am J Cardiol 1987; 59: 14–19.
Waller BF, Fry ET, Hermiller JB, Peters T, Slack JD. Nonatherosclerotic causes of coronary artery narrowing-Part III. Clin Cardiol 1996; 19: 656–661.
Maseri AB, L’Abbatte G and A. Coronary vasopasm as a possible cause of myocardial infarction. N Eng J Med 1978; 299: 1271–1277.
Schachinger V, Britten MB, Elsner M, Walter DH, Scharrer I, Zeiher AM. A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation 1999; 100: 1502–1508.
Hamsten A, Walldius G, Szamosi A, Dahlen G, de Faire U. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation 1986; 73: 1097–1110.
Pitts WR, Lange RA, Cigarroa JE, Hillis LD. Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management. Prog Cardiovasc Dis 1997; 40: 65–76.
Hollander JE. Cocaine-associated myocardial infarction. J R Soc Med 1996; 89: 443–447.
Boghdadi MS, Henning RJ. Cocaine: pathophysiology and clinical toxicology. Heart Lung 1997; 26: 466–485.
Friedman W. Congenital heart disease in infancy and childhood. In: Braunwald E. ed. Heart Disease. W.B. Saunders, Philadelphia, 1997.
Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991; 67: 1185–1189.
PDAY Study Group. Relationship of atherosclerosis in young men to serum lippoprotein cholesterol concentrations and smoking. JAMA 1990; 264: 3018–3024.
Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease [see comments]. N Engl J Med 1993; 328: 313–318.
Genest J Jr, Cohn JS. Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol 1995; 76: 8A - 20A.
Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol 2000; 15: 416–421.
Franklin, BA, Fletcher GF, Gordon NF, Noakes TD, Ades PA, Balady GJ. Cardiovascular evaluation of the athlete. Issues regarding performance, screening and sudden cardiac death. Sports Med 1997; 24: 97–119.
Chen L, Chester M, Kaski JC. Clinical factors and angiographie features associated with premature coronary artery disease. Chest 1995; 108: 364–369.
Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. Am J Cardiol 1997; 79: 756–762.
McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 1997; 17: 95–106.
Strong JP, Malcom GT, Oalmann MC. Environmental and genetic risk factors in early human atherogenesis: lessons from the PDAY study. Pathobiological Determinants of Atherosclerosis in Youth. Pathol Int 1995; 45: 403–408.
Strong JP, Malcom GT, Oalmann MC, Wissler RW. The PDAY Study: natural history, risk factors, and pathobiology. Pathobiological Determinants of Atherosclerosis in Youth. Ann NY Acad Sci 1997; 811: 226–237.
Zahger D, Cercek B, Cannon CP, et al. How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) [see comments]. Am J Cardiol 1995; 75: 232–236.
Beigel Y, George J, Leibovici L, Mattityahu A, Sclarovsky S, Blieden L. Coronary risk factors in children of parents with premature coronary artery disease. Acta Paediatr 1993; 82: 162–165.
Despres JP Lamarche B, Mauriege P, Cantin B, Lupien PJ, Dagenais GR. Risk factors for ischaemic heart disease: is it time to measure insulin? Eur Heart J 1996; 17: 1453–1454.
Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circulation 2001; 103: 2225–2229.
Kontula K, Ehnholm C. Regulatory mutations in human lipoprotein disorders and atherosclerosis. Curr Opin Lipidol 1996; 7: 64–68.
Fortmann SP, Marcovina SM. Lipoprotein(a), a clinically elusive lipoprotein particle [editorial; corn-ment]. Circulation 1997; 95: 295–296.
Valentine RJ, Grayburn PA, Vega GL, Grundy SM. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994; 154: 801–806.
Wilcken DE, Wang XL, Greenwood J, Lynch J. Lipoprotein(a) and apolipoproteins B and A-1 in children and coronary vascular events in their grandparents [see comments]. J Pediatr 1993; 123: 519–526.
Ridker PM, Hennekens CH. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195–2199.
White AL, Lanford RE. Biosynthesis and metabolism of lipoprotein (a). Curr Opin Lipidol 1995; 6: 75–80.
Scanu AM. Structural and functional polymorphism of lipoprotein(a): biological and clinical implications. Clin Chem 1995; 41: 170–172.
Shaukat N, de Bono DP, Jones DR. Like father like son? Sons of patients of European or Indian origin with coronary artery disease reflect their parents’ risk factor patterns. Br Heart J 1995; 74: 318–323.
Enas EA, Dhawan J, Petkar S. Coronary artery disease in Asian Indians: lessons learnt and the role of lipoprotein(a). Indian Heart J 1997; 49: 25–34.
Angelin B. Therapy for lowering lipoprotein (a) levels. Curr Opin Lipidol 1997; 8: 337–341.
Calabresi L, Franceschini G. High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. Curr Opin Lipidol 1997; 8: 219–224.
Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996; 7: 209–216.
Kwiterovich PO Jr. Diagnosis and management of familial dyslipoproteinemia in children and adolescents. Pediatr Clin North Am 1990; 37: 1489–1523.
Schaefer EJ. Familial lipoprotein disorders and premature coronary artery disease. Med Clin North Am 1994; 78: 21–39.
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–418.
De Man FH, Cabezas MC, Van Barlingen HH, Erkelens DW, de Bruin TW. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 1996; 26: 89–108.
de Faire U, Ericsson, CG, Grip L, Nilsson J, Svane B, Hamsten A. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996; 17 (Suppl. F): 37–42.
Austin MA, Hokanson JE. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. Med Clin North Am 1994; 78: 99–115.
Avogaro P, Ghiselli G, Soldan S, Bittolo Bon G. Relationship of triglycerides and HDL cholesterol in hypertriglyceridemia. Atherosclerosis 1992; 92: 79–86.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results ofAFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622.
Clearfield M, Whitney EJ, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. J Cardiovasc Risk 2000; 7: 125–133.
Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477–484.
Assmann G, von Eckardstein A, Funke H. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 1993;87:III28–III34.
Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991; 14: 461–469.
Genest JJ Jr, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16: 1114–1119.
Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996; 94: 2154–2158.
Fowler B. Disorders of homocysteine metabolism. J Inherit Metab Dis 1997; 20: 270–285.
Boers GH. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997; 78: 520–522.
Duell PB, Malinow MR. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 1997; 8: 28–34.
Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995; 332: 286–291.
Christen WG, Ridker PM. Blood levels of homocysteine and atherosclerotic vascular disease. Curr Atheroscler Rep 2000; 2: 194–199.
Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481–2485.
Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704–709.
Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593–1600.
Kang SS, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992; 12: 279–298.
Rallidis LS, Papageorgakis NH, Megalou AA, Anagnostou ED, Chatzidimitriou GI, Tsitouris GK. Fibrinogen in the offspring of men with premature coronary artery disease. Eur Heart J 1995; 16: 1814–1818.
Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol 1997; 8: 320–328.
Hamsten A, Blomback M, Wiman B, et al. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58–66.
Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001; 104: 2641–2644.
Wolfe J, Vacek ML. Myocardial infarction in the young: angiographic features and risk factor analysis of patients with MI at or before the age of 35. Chest 1994; 94: 926–930.
Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995; 26: 654–661.
Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: 56–62.
Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease [see comments]. Circulation 1995; 92: 2333–2342.
Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365–372.
Dollar AL, Kragel AH, Fernicola DJ, Waclawiw MA, Roberts WC. Composition of atherosclerotic plaques in coronary arteries in women less than 40 years of age with fatal coronary artery disease and implications for plaque reversibility. Am J Cardiol 1991; 67: 1223–1227.
Corrado D, Thiene G, Pennelli N. Sudden death as the first manifestation of coronary artery disease in young people (less than or equal to 35 years). Eur Heart J 1988; 9 (Suppl. N): 139–144.
Berenson GS, Srinivasan SR, Nicklas TA, Johnson CC. Prevention of adult heart disease beginning in the pediatric age. Cardiovasc Clin 1990; 20: 21–45.
Stare TJ, Belamarich PF, Shea S, et al. Family history fails to identify many children with severe hypercholesterolemia. Am J Dis Child 1991; 145: 61–64.
Muhonen LE, Burns TL, Nelson RP, Lauer RM. Coronary risk factors in adolescents related to their knowledge of familial coronary heart disease and hypercholesterolemia: the Muscatine Study. Pediatrics 1994; 93: 444–451.
Zehr KJ, Lee PC, Poston RS, Gillinov AM, Greene PS, Cameron DE. Two decades of coronary artery bypass graft surgery in young adults. Circulation 1994; 90: 11133–11139.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–2497.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Fang, J.C., Plutzky, J. (2003). Myocardial Infarction in the Younger Patient. In: Cannon, C.P. (eds) Management of Acute Coronary Syndromes. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-351-4_22
Download citation
DOI: https://doi.org/10.1007/978-1-59259-351-4_22
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-58829-309-1
Online ISBN: 978-1-59259-351-4
eBook Packages: Springer Book Archive